TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10433013
Drug: Anti-carbonic anhydrase
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-carbonic anhydrase II antibody testing in patients with obstructive jaundice (n=10)
Study: 1387774
Drug: Ondansetron 4
Normalized name: ondansetron 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 4 mg orally once daily for 3-5 consecutive days
Study: 6660847
Drug: Amoxicillin combined
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin combined with clavulanic acid (ACA)
Study: 29289538
Drug: Omega-3 carboxylic
Normalized name: omega-3 carboxylic acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 carboxylic acids (OM3-CA) 2 g daily
Study: 29289538
Drug: Olive oil
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil 2 g daily
Study: 27091416
Drug: Control (patient's
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (patient's choice with physician's advice of low-dose cytarabine or supportive care)
Study: 21889769
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with statins and fenofibric acid (FA)
Study: 10548322
Drug: High-fruit and
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fruit and -vegetable diet (9 daily servings)
Study: 2006616
Drug: Nifedipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (20 mg 3 times daily)
Study: 7124629
Drug: Verapamil (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (120 mg 3 times daily)
Study: 28662808
Drug: Metallic drug-eluting
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metallic drug-eluting stent (DES)
Study: 30728074
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose Shilajit (500 mg·d‐1)
Study: 30728074
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose Shilajit (250 mg·d‐1)
Study: 28068560
Drug: Sarpogrelate 300
Normalized name: Sarpogrelate
DrugBank: Sarpogrelate (DB12163)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarpogrelate 300 mg/day plus aspirin 100 mg/day (SPG + ASA group)
Study: 28068560
Drug: Aspirin 100
Normalized name: aspirin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 100 mg/day alone (ASA group)
Study: 26091087
Drug: telephone-delivered cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: telephone-delivered cognitive behavioural treatment (CBT) for 8 weeks
Study: 24919799
Drug: Needling device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Needling device treatment (3 treatments at 2-week intervals)
Study: 23390653
Drug: Original stimulating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Original stimulating programs for correction of cognitive decline (computer programs, 20-30 minutes daily, 5 times a week for 14 days)
Study: 23390653
Drug: Traditional methods
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional methods of treatment
Study: 12205254
Drug: Sucrose (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucrose (0.1 mL of 24%) administered orally up to 3 times, 2 minutes apart for every invasive procedure during a 7-day period
Study: 12205254
Drug: Sterile water
Normalized name: sterile water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile water administered orally up to 3 times, 2 minutes apart for every invasive procedure during a 7-day period
Study: 30909680
Drug: Thiocochlicoside (group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiocochlicoside (group A) along with paracetamol and lornoxicam I.V.
Study: 30909680
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (group B) without thiocochlicoside, receiving paracetamol and lornoxicam I.V.
Study: 25837041
Drug: Endoscopic lung
Normalized name: beef lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic lung sealant (ELS) plus medical treatment
Study: 22905666
Drug: Epidural tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural tramadol (3 mg/kg)
Study: 22905666
Drug: Epidural lignocaine
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural lignocaine (4 mg/kg)
Study: 17704869
Drug: Rofecoxib 25
Normalized name: rofecoxib 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib 25 mg PO, Metoclopramide 10 mg, Dexamethasone 4 mg, Ondansetron 4 mg IV
Study: 11798012
Drug: Panax ginseng
Normalized name: Panax Ginseng
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panax ginseng (PG) - 2 g/day dried root equivalent
Study: 11798012
Drug: Eleutherococcus senticosus
Normalized name: Eleutherococcus Senticosus Root
DrugBank: Eleuthero (DB14303)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eleutherococcus senticosus (ES) - 4 g/day dried root equivalent
Study: 7849498
Drug: Clonidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (300 micrograms orally, 1 h prior to morphine)
Study: 3347080
Drug: Alcohol (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.8 ml of absolute alcohol per kg of body weight)
Study: 29737150
Drug: Pycnogenol® 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pycnogenol® 150 mg/day
Study: 20798386
Drug: High-dose isoflavones
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose isoflavones (20 g of soy protein containing 160 mg of total isoflavones)
Study: 20798386
Drug: Placebo (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (20 g whole milk protein)
Study: 20798386
Drug: High-dose isoflavones
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose isoflavones
Study: 18781287
Drug: Topical azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical azithromycin ophthalmic solution 1% plus warm compresses
Study: 16569248
Drug: Early administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early administration of atropine during dobutamine stress echocardiogram (group C at 40 mcg/kg/min of dobutamine)
Study: 14599854
Drug: Intravenous daclizumab
Normalized name: Daclizumab
DrugBank: Daclizumab (DB00111)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous daclizumab infusions (anti-IL-2 receptor alpha)
Study: 14599854
Drug: Subcutaneous daclizumab
Normalized name: Daclizumab
DrugBank: Daclizumab (DB00111)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subcutaneous daclizumab formulation
Study: 14599854
Drug: Intravenous daclizumab
Normalized name: Daclizumab
DrugBank: Daclizumab (DB00111)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous daclizumab infusions (6-week intervals)
Study: 14599854
Drug: Intravenous daclizumab
Normalized name: Daclizumab
DrugBank: Daclizumab (DB00111)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous daclizumab infusions (2- to 4-week intervals)
Study: 7570621
Drug: Inhalation exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation exposure to toluene diisocyanate (TDI) vapors
Study: 18362100
Drug: Cod liver
Normalized name: Cod Liver Oil
DrugBank: Cod liver oil (DB11321)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cod liver oil (10 g containing 2.2 g of n-3 EFAs)
Study: 18362100
Drug: Placebo (air-filled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (air-filled identical capsules)
Study: 1358003
Drug: High-dose esmolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose esmolol (300 micrograms.kg‐1.min‐1)
Study: 1358003
Drug: Medium-dose esmolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-dose esmolol (200 micrograms.kg‐1.min‐1)
Study: 1358003
Drug: Low-dose esmolol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose esmolol (100 micrograms.kg‐1.min‐1)
Study: 2997306
Drug: Pentopril (CGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentopril (CGS 13945) 125 mg capsules administered in the fasting state
Study: 2997306
Drug: Pentopril (CGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentopril (CGS 13945) 125 mg capsules administered after ingestion of a standardized meal
Study: 30887250
Drug: PF-06650808 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06650808 at dose levels ≤2.0 mg/kg
Study: 30236568
Drug: Warm intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warm intravenous fluids (Ringer's solution at 38°C)
Study: 30236568
Drug: Room temperature
Normalized name: ROOM DEODORIZER POWDER MENTOR #3202
Approvals — FDA: no, EMA: no, PMDA: no
Description: Room temperature intravenous fluids (Ringer's solution)
Study: 25008546
Drug: Tozadenant 120
Normalized name: Tozadenant
DrugBank: Tozadenant (DB12203)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tozadenant 120 mg twice daily
Study: 25008546
Drug: Tozadenant 180
Normalized name: Tozadenant
DrugBank: Tozadenant (DB12203)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tozadenant 180 mg twice daily
Study: 21753727
Drug: NGX-4010 (capsaicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: NGX-4010 (capsaicin 8% patch)
Study: 22067661
Drug: Low-dose capsaicin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose capsaicin (0.04% control patch)
Study: 22067661
Drug: Low-dose capsaicin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose capsaicin (30-minute control)
Study: 22067661
Drug: Low-dose capsaicin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose capsaicin (60-minute control)
Study: 19400487
Drug: Hypobaric bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypobaric bupivacaine 0.15% 4.5 mg (3 ml)
Study: 19400487
Drug: Hypobaric bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypobaric bupivacaine 0.15% 6.0 mg (4 ml)
Study: 19400487
Drug: Hypobaric bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypobaric bupivacaine 0.15% 7.5 mg (5 ml)
Study: 14722542
Drug: Hyoscine N-butyl
Normalized name: n-butyl acrylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyoscine N-butyl bromide (40 mg)
Study: 3400079
Drug: Acitretin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acitretin (100 mg)
Study: 3400079
Drug: Etretinate (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etretinate (100 mg)
Study: 30821829
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy for 5 years (HPS trial)
Study: 27262301
Drug: FEC-chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FEC-chemotherapy
Study: 26701648
Drug: Intravenous thrombolysis
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous thrombolysis (rt-PA)
Study: 10352369
Drug: Standardized acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized acupuncture treatment
Study: 29572107
Drug: Loteprednol etabonate
Normalized name: Loteprednol Etabonate
DrugBank: Loteprednol etabonate (DB14596)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Loteprednol etabonate 0.5% ophthalmic suspension
Study: 25966339
Drug: cART initiated
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: cART initiated one week after TB therapy
Study: 25966339
Drug: cART initiated
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: cART initiated four weeks after TB therapy
Study: 25966339
Drug: cART initiated
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: cART initiated eight weeks after TB therapy
Study: 23089653
Drug: Intraoral mucoadhesive
Normalized name: testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoral mucoadhesive tablet of amitriptyline
Study: 22358273
Drug: BiPAP® group
Approvals — FDA: no, EMA: no, PMDA: no
Description: BiPAP® group (BG) with conventional respiratory therapy and BiPAP® for 30 minutes twice a day
Study: 22358273
Drug: Control Group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control Group (CG) with conventional respiratory therapy only
Study: 6655704
Drug: Sex therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sex therapy
Study: 12708976
Drug: DB PCFC
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: DB PCFC with metabisulfite‐free seasoning (up to 1340 mg)
Study: 8811328
Drug: High lipid
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: High lipid meal (whipped cream)
Study: 1547673
Drug: Long-acting zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting zinc insulin (Ultratard HM) before the evening meal
Study: 1547673
Drug: Intermediate isophane
Normalized name: insulin isophane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate isophane insulin (Protaphane HM) before the evening meal
Study: 21638048
Drug: Toremifene (TOR)
DrugBank: Toremifene (DB00539)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Toremifene (TOR) 40 mg daily
Study: 21638048
Drug: Anastrozole (ANA)
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anastrozole (ANA) 1 mg daily
Study: 11886769
Drug: 7-day transdermal
Normalized name: buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 7-day transdermal sequential estradiol/levonorgestrel patch (Fem7 Combi; 50 microg estradiol/10 microg levonorgestrel per 24 h)
Study: 7999858
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human growth hormone (rhGH) at a dosage of 28-30 IU/m2/week for at least 12 months
Study: 3045717
Drug: Norfloxacin 400
Normalized name: norfloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin 400 mg twice daily for three days
Study: 3045717
Drug: Trimethoprim 300
Normalized name: trimethoprim 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim 300 mg once daily for three days
Study: 27843040
Drug: Rivaroxaban 10
Normalized name: rivaroxaban 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 10 mg by mouth daily starting postoperative day 1 for 15 days
Study: 8826488
Drug: 5% lidocaine
Normalized name: LIDOCAINE 5 g in 100 g TOPICAL CREAM [Healcome Tattoo Numbing Cream 5% Lidocaine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% lidocaine patches applied for 12 hours in two of four sessions
Study: 8826488
Drug: Vehicle patches
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle patches applied for 12 hours in one session
Study: 8826488
Drug: No-treatment observation
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-treatment observation session
Study: 30382274
Drug: Daily dose
Normalized name: LENVIMA 8mg Daily Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dose of 8 g of dried grape pomace
Study: 22525652
Drug: Creatine ingestion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine ingestion (0.3 g/kg/die for 5 consecutive days)
Study: 7677387
Drug: Moxonidine 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxonidine 0.1 mg
Study: 2196934
Drug: Doxycycline 200
Normalized name: doxycycline 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 200 mg orally at the time of IUCD insertion
Study: 31632316
Drug: Endotoxin administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Endotoxin administration
Study: 24915210
Drug: Nasal mupirocin
Normalized name: mupirocin Nasal Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal mupirocin ointment applied twice daily for 5 days before surgery
Study: 24915210
Drug: Nasal povidone-iodine
Normalized name: povidone-iodine Nasal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal povidone-iodine solution applied twice into each nostril within 2 hours of surgical incision
Study: 18378381
Drug: Simvastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (10 mg/day)
Study: 11477342
Drug: Gemfibrozil (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemfibrozil (dose adjusted for renal function)
Study: 9667249
Drug: 9-aminocamptothecin (9-AC)
Normalized name: 9-aminocamptothecin
DrugBank: 9-aminocamptothecin (DB12515)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9-aminocamptothecin (9-AC) infused over 72 hours at an initial dose rate of 40 microg/m2/h every 3 weeks with dose adjustments based on toxicity.
Study: 9667249
Drug: Granulocyte-colony stimulating
Normalized name: Granulocyte colony-stimulating factor pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Granulocyte-colony stimulating factor (G-CSF) administered to the subsequent 29 patients on all cycles.
Study: 8092339
Drug: Naltrexone, 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone, 50 mg p.o.
Study: 25947167
Drug: Electroacupuncture (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture (EA) - 10 sessions, 30 minutes each, 2-10 Hz, intensity by tolerance, twice per week
Study: 23357545
Drug: Essential amino
Normalized name: Essential amino acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Essential amino acids (EAA) 6.7 g
Study: 12061999
Drug: Prophylactic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic treatment including lipid lowering drugs (52%), beta-blockers (50%), antiplatelet drugs (87%), ACE inhibitors (32%), nitrates (52%), calcium antagonists (31%), oral anticoagulants (8%)
Study: 9691642
Drug: Intracervical application
Normalized name: eladocagene exuparvovec
DrugBank: Eladocagene exuparvovec (DB16780)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracervical application of 0.5 mg dinoprostone gel
Study: 195328
Drug: Regimen I:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen I: 3 months of INH + RMP (2/7) in hospital, followed by 6 months of INH + SM (2/7) or INH + EMB (2/7) in ambulatory treatment.
Study: 195328
Drug: Regimen II:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen II: 3 months of INH + SM + EMB (2/7) in hospital, followed by 6 months of INH + SM (2/7) or INH + EMB (2/7) in ambulatory treatment.
Study: 31691018
Drug: p-synephrine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: p-synephrine (3 mg kg-1)
Study: 28291262
Drug: Bumetanide (0.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bumetanide (0.5, 1.0 or 2.0 mg twice daily)
Study: 21078615
Drug: ARC1779 (83
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARC1779 (83 and 250 nmol/L)
Study: 21078615
Drug: abciximab (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: abciximab (100 nmol/L)
Study: 19156121
Drug: Memantine (M)
DrugBank: Memantine (DB01043)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Memantine (M) 5 mg daily for 1 week, then 10 mg daily for 1 week, then 15 mg daily for 1 week, then 20 mg daily from the 4th week
Study: 16820073
Drug: Imiquimod 5%
Normalized name: Imiquimod 5% Topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod 5% cream for 4 weeks
Study: 16820073
Drug: Imiquimod 5%
Normalized name: Imiquimod 5% Topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod 5% cream for 8 weeks
Study: 16820073
Drug: Imiquimod 5%
Normalized name: Imiquimod 5% Topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod 5% cream for 12 weeks
Study: 16820073
Drug: Imiquimod 5%
Normalized name: Imiquimod 5% Topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod 5% cream for 16 weeks
Study: 12669393
Drug: Wide-field hemibody
Normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wide-field hemibody irradiation or systemic administration of radioisotopes
Study: 11783142
Drug: Baoyuan Qiangshen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baoyuan Qiangshen Capsule No. II (BYQS) combined with Lotensin
Study: 2196622
Drug: Nefazodone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefazodone (100 mg to 200 mg daily)
Study: 28880941
Drug: One-day educational
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-day educational program for health workers in intravenous treatment
Study: 28880941
Drug: Intravenous antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous antibiotics in nursing homes
Study: 28880941
Drug: Intravenous fluids
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fluids in nursing homes
Study: 19640363
Drug: Market capsule
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Market capsule formulation
Study: 19640363
Drug: Market suspension
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Market suspension
Study: 19640363
Drug: Clinical trial
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical trial suspension
Study: 19640363
Drug: All formulations
Normalized name: Novel Influenza-H1N1-09, all formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: All formulations (market suspension, clinical trial suspension, market capsule)
Study: 17635595
Drug: Naratriptan 1
Normalized name: naratriptan 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naratriptan 1 mg twice daily for 6 days
Study: 12200522
Drug: Bronchial asthma
Normalized name: CVS Bronchial Asthma Relief 12.5mg-200mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bronchial asthma patients after 3 weeks of treatment with oral glucocorticoids (n=20)
Study: 9866667
Drug: Mupirocin cream
Normalized name: Mupirocin Cream
DrugBank: Mupirocin (DB00410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mupirocin cream applied topically 3 times daily
Study: 9866667
Drug: Oral cephalexin
Normalized name: Cephalexin
DrugBank: Cephalexin (DB00567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cephalexin given 4 times daily
Study: 7622767
Drug: 0.05 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mg/m2 IFN-gamma treatment
Study: 32041
Drug: Metoprolol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (10 mg i.v.)